Geographic Atrophy (GA)

Treatment using Syfovre® Injections for Geographic Atrophy (GA)

What is Geographic Atrophy?

Geographic Atrophy is an advanced form of age-related macular degeneration (AMD) that leads to gradual and permanent loss of central vision. It affects the central area of the retina, known as the macula—impacting reading, driving, and recognising faces.

Syfovre® (pegcetacoplan) is the first and only FDA-approved treatment specifically designed to slow the progression of GA. It is now available in Australia and administered via intravitreal injection (into the eye).

How Does It Work?

Syfovre targets and blocks a part of the immune system called complement C3, which is overactive in GA. By slowing the damage to retinal cells, Syfovre can help preserve vision for longer.

What to Expect During Treatment

  • Frequency: Every two months
  • Procedure: The injection takes just a few minutes and is performed in the clinic under sterile conditions with local anaesthetic
  • Recovery: Most patients return to normal activities by the next day

Benefits

  • Slows the progression of Geographic Atrophy and retinal cell loss
  • May preserve reading and visual function for longer
  • Early treatment can offer better long-term outcomes

Risks and Side Effects

  • Common: Mild eye irritation, surface bleed, floaters, or discomfort after injection
  • Rare: Infection, inflammation and increased risk of wet AMD

The potential risks and benefits will be discussed in detail with you.

Is Syfovre Right for You?

Syfovre is suitable for patients with confirmed Geographic Atrophy not caused by wet AMD. Early detection and timely treatment offer the best chances of preserving vision.

To make an appointment with one of our Retinal Specialists, please call 9411 5000 

 

References

  1. Heier JS, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. 2023 Oct 21;402(10411):1434-1448
  2. Fu DJ, et al. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. JAMA Ophthalmol. 2024;142(6):548–558. doi:10.1001/jamaophthalmol.2024.1269
  3. Apellis Pharmaceuticals. Syfovre Patient Information and Support. https://syfovre.com